Two mutations in the CFTR gene linked to cystic fibrosis were corrected in patient-derived cells using CRISPR/Cas9 gene editing, researchers reported in Nature Communications. The technology restored CFTR function in cells carrying either the wild-type or mutated versions of CFTR, and in lung cells and mini-intestines grown from CF patients' intestinal epithelial cells, while leaving non-mutated DNA unaffected.
CRISPR corrects CF genetic mutations in patient-derived organoids
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.